New European consortium formed to help further advance development of a GSK/NIH Ebola candidate vaccine
- Details
- Category: GlaxoSmithKline
A new European consortium has been formed including GSK and three leading research institutions to help further advance development of a candidate vaccine against Ebola, which is being co-developed by GSK and the US National Institutes of Health (NIH).
Abbott completes acquisition of Veropharm
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer. Abbott has had a presence in Russia for nearly 40 years and, in line with its long-term commitment to growing global healthcare markets and capabilities, the company is committed to providing a reliable supply of its healthcare products to Russian patients.
Pfizer expands rare disease research with establishment of gene therapy platform
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) announced today two strategic decisions to expand the company's rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients.
Jury verdict favours AstraZeneca in Nexium antitrust litigation
- Details
- Category: AstraZeneca
AstraZeneca today announced that a jury in the US District Court for the District of Massachusetts returned a verdict in favour of AstraZeneca in a Multi-District antitrust case filed by various purchaser groups challenging the previous settlement of Nexium patent litigation with Ranbaxy.
Bristol-Myers Squibb Foundation awards nine grants to support care for high-risk patients with hepatitis B and C in China and India
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb Foundation today announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vulnerable, high-risk patient populations.
Amgen and AstraZeneca announce positive results from third and final pivotal Phase III study of Brodalumab in patients with moderate-to-severe plaque psoriasis
- Details
- Category: AstraZeneca
AstraZeneca and Amgen have announced that AMAGINE-2™, a pivotal, multi-arm Phase III trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12.
GSK statement on first phase 1 trial results of a candidate Ebola vaccine
- Details
- Category: GlaxoSmithKline
First results from a small phase 1 trial published yesterday in the New England Journal of Medicine show that a GSK/NIH Ebola candidate vaccine was well-tolerated and produced an immunological response in each of the 20 healthy adult volunteers in the USA who received it.
More Pharma News ...
- Bristol-Myers Squibb and Five Prime Therapeutics announce exclusive clinical collaboration
- Novartis Foundation symposium showcases sustainable healthcare interventions
- Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin
- Novo Nordisk second best in the world at providing access to medicine
- Bristol-Myers Squibb to construct a new large-scale biologics manufacturing facility in Ireland
- AstraZeneca announces initiation of development programme for BRILINTA® reversal agent
- Roche to invest 450 million Swiss Francs in new diagnostic manufacturing facility in China